The main route of causing various chronic diseases is the presence of specific proteins namely antigens, on the surface of pathogenic organisms. The immune system plays an important role in fighting against these antigens by producing three types of protein namely complement protein, antibodies, and interferons. However, antibodies, specialized proteins having specific antigen binding site (paratope), act as the first line of defense against them. There are different classes of antibodies based on their production, sources, and immunoglobulin gene (Ig) sequence. Naturally, antibodies are formed by plasma or B or T cells in the body. Moreover, they have high specificity, strong affinity, and long term memory against specific pathogen. In addition, antibodies have specific region called antigen binding fragment (Fab) that vary as per the antigen molecule. This makes them highly specific for particular pathogen. Such advantages proved them an ideal model for research purpose. “Meticulous Research” in its latest publication states that, the “global market for research antibodies and reagents market is expected to grow at a CAGR of 6.5% from 2018 to 2023 to reach $13,276.5 million by 2023.”
This growth is primarily driven by the increasing proteomics and genomics research studies, increase in the funding for research activities, and growing industry-academia collaborations.
The research & development activities in academic institutes and government research institutes have significantly increased in the last 2-3 decades with rising funding from various government organizations. This funding is mainly driven by rising health care concerns globally, complexity of clinical trials, and higher failure of drugs in earlier phase studies.
Don’t miss out on business opportunities in Research Antibodies And Reagents Market– Global Opportunity Analysis And Industry Forecast (2018-2023)
In the U.S., the government R&D spending agencies such as Department of Defense (DOD), National Institute of Health (NIH), Department of Energy (DOE), and National Aeronautics and Space Administration (NASA) account for around 90% of the total R&D investments globally. The National Institutes of Health (NIH) is the largest source of funding for basic and applied research in the world, provides approximately 84% of NIH funds to universities, medical schools, and other research institutes. According to the U.S. Department of Health & Human Services (HHS), the budget on research spending by National Institutes of Health has increased to USD 33,136 million for the FY 2017 from USD 32,311 million for the FY 2016 and USD 30,311 million for the FY 2015. And out of this total budget, around 52% is dedicated for the basic biomedical and behavioral research which involved proteomics studies carried out to understand how the basic components of life function.
According to the Research America, investment in medical and health research and development by the U.S. has increased by 13.3% between 2013 and 2015. In 2015, total expenditure on R&D in the U.S. was USD 158.7 billion. Industry, including pharmaceutical, medical technology, biotechnology and health IT companies, accounted for the largest share of the U.S. investment in medical and health R&D over the reporting period. This was attributed to increase in research activities in pharmaceutical and biotechnology industries, research institutes, and high demand of drugs for the treatment of chronic illness. In addition to this, according to the WHO, it has been projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide with number of people with diabetes will increase by 2.5-fold till 2020. Thus, the increased complexities and mortality rate due to chronic diseases such as cardiovascular diseases, diabetes, cancers, and chronic respiratory diseases fuels the funding for research.
In addition, the government of the U.S. took an initiative to accelerate high growth entrepreneurship throughout the nation by investing in small biomedical companies, which helps to increase the innovation. The Indian government policy has been playing crucial role, by reducing approval time for new drug molecule to boost the foreign investment in the drug discovery industries. Mainly, basic research funded by federal agencies including NIH, NSF, DOE SC and USDA contributed the development of new therapeutics that have improved health, increased rate of pharmaceutical industry, and launched multibillion dollar biotechnology industry. Thus, increasing R&D spending support the development of new therapeutics across the globe; thereby driving the research antibodies and reagents market in the coming years.
The report provides meticulous analysis of research antibodies and reagents market on the basis of product (reagents and research antibodies), by technology (western blotting, immunofluorescence, immunosorbent assays, flow cytometry, immunohistochemistry, and immunoprecipitation), by application (proteomics, drug discovery & development, and genomics), and by end user (pharmaceutical & biotechnology industry, academic & research institutes, and contract research organizations), and geography.
The key players analyzed in the Research Antibodies and Reagents Market are GE Healthcare (U.S.), Merck & Co., Inc.(U.S.), Thermo Fisher Scientific Inc.(U.S.), Amgen Inc.(U.S.), Sanofi (France), F. Hoffmann La-Roche Ltd (Switzerland), Rockland Immunochemicals Inc.(U.S.), Johnson & Johnson (U.S.), Agilent Technologies, Inc.(U.S.), Eli Lilly and Company (U.S.), Becton Dickinsonand Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc.(U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc.(U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology, Inc.(U.S.), BioLegend, Inc.(U.S.), Abcam PLC (U.K.), and Cell Signaling Technology, Inc.(U.S.).
For detailed Table of Content; Download free sample report here
Browse Adjacent Markets @ Biotechnology Research Reports & Consulting